Human igg1 antibodies suppress angiogenesis in a target-independent manner

Signal Transduction and Targeted Therapy

Volumn 1, Issue , 2016, Pages

  Bogdanovich, Sasha ^a   Kim, Younghee ^a   Mizutani, Takeshi ^a,b   Yasuma, Reo ^a,c   Tudisco, Laura ^d   Cicatiello, Valeria ^d,e   Bastos Carvalho, Ana ^a   Kerur, Nagaraj ^a   Hirano, Yoshio ^a   Baffi, Judit Z ^a   Tarallo, Valeria ^a,d   Li, Shengjian ^a   Yasuma, Tetsuhiro ^a   Arpitha, Parthasarathy ^a   Fowler, Benjamin J ^a   Wright, Charles B ^a   Apicella, Ivana ^d   Greco, Adelaide ^f,g   Brunetti, Arturo ^f,g   Ruvo, Menotti ^h   Sandomenico, Annamaria ^h   Nozaki, Miho ^b   Ijima, Ryo ^c   Kaneko, Hiroki ^c   Ogura, Yuichiro ^b   Terasaki, Hiroko ^c   Ambati, Balamurali K ^i,j   Leusen, Jeanette HW ^k   Langdon, Wallace Y ^l   Clark, Michael R ^m   Armour, Kathryn L ^m   Bruhns, Pierre ^n,o   Verbeek, J Sjef ^p   Gelfand, Bradley D ^a,q   De Falco, Sandro ^d,r   Ambati, Jayakrishna ^a   more..

^a UNIVERSITY OF KENTUCKY   (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^e Bio Ker MultiMedica Group   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^h CNR   (Italy)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ INSTITUT PASTEUR   (France)

^o INSERM   (France)

^p LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^q UNIVERSITY OF KENTUCKY   (United States)

^r IRCCS MULTIMEDICA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009106495     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/sigtrans.2015.1     Document Type: Article

References (92)

1. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9: 767–774.
2. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–4599.
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391–400.
4. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
5. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951–961.
6. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007; 104: 3478–3483.
7. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49: 522–527.
8. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007; 91: 804–807.
9. Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, Goldenberg-Cohen N. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis 2009; 15: 2326–2338.
10. Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 2009; 42: 90–95.
11. Avisar I, Weinberger D, Kremer I. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model. Curr Eye Res 2010; 35: 108–115.
12. Dastjerdi MH, Saban DR, Okanobo A, Nallasamy N, Sadrai Z, Chauhan SK et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 2010; 51: 2411–2417.
13. Akkoyun I, Karabay G, Haberal N, Dagdeviren A, Yilmaz G, Oto S et al. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model. Acta Ophthalmol 2012; 90: 564–570.
14. Rabinowitz R, Priel A, Rosner M, Pri-Chen S, Spierer A. Avastin treatment reduces retinal neovascularization in a mouse model of retinopathy of prematurity. Curr Eye Res 2012; 37: 624–629.
15. Unkeless JC, Eisen HN. Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages. J Exp Med 1975; 142: 1520–1533.
16. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991; 9: 457–492.
17. Nimmerjahn F, Ravetch JV. Divergent Immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005; 310: 1510–1512.
18. Kim JH, Seo HW, Han HC, Lee JH, Choi SK, Lee D. The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study. Korean J Ophthalmol 2013; 27: 235–242.
19. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258–1267.
20. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932–936.
21. Silver J. Drugs for macular degeneration, price discrimination, and Medicare's responsibility not to overpay. JAMA 2014; 312: 23–24.
22. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15: 1023–1030.
23. Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci USA 2009; 106: 7137–7142.
24. Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y et al. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 2014; 346: 1000–1003.
25. Mizutani T, Fowler BJ, Kim Y, Yasuma R, Krueger LA, Gelfand BD et al. Nucleoside reverse transcriptase inhibitors suppress laser-induced choroidal neovascularization in mice. Invest Ophthalmol Vis Sci 2015; 56: 7122–7129.
26. Hirano Y, Yasuma T, Mizutani T, Fowler BJ, Tarallo V, Yasuma R et al. IL-18 is not therapeutic for neovascular age-related macular degeneration. Nat Med 2014; 20: 1372–1375.
27. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol 1998; 152: 1667–1679.
28. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591–597.
29. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 865–881.
30. Marino M, Ruvo M, De Falco S, Fassina G. Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat Biotechnol 2000; 18: 735–739.
31. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl JMed2006; 355: 1432–1444.
32. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
33. Kami J, Muranaka K, Yanagi Y, Obata R, Tamaki Y, Shibuya M. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. Jpn J Ophthalmol 2008; 52: 91–98.
34. Takahashi H, Tamaki Y, Ishii N, Oikawa N, Mizuguchi E, Francis JH et al. Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Curr Eye Res 2008; 33: 1002–1010.
35. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 2009; 460: 225–230.
36. Ueno S, Pease ME, Wersinger DM, Masuda T, Vinores SA, Licht T et al. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 2008; 217: 13–22.
37. Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest 2006; 116: 422–429.
38. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143: 2595–2601.
39. Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 1989; 259: 347–353.
40. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK et al. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012; 189: 3430–3438.
41. Mancardi DA, Iannascoli B, Hoos S, England P, Daeron M, Bruhns P. FcγRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118: 3738–3750.
42. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288: 371–378.
43. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640–5649.
44. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci USA 2012; 109: 6181–6186.
45. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716–3725.
46. Ben Mkaddem S, Hayem G, Jonsson F, Rossato E, Boedec E, Boussetta T et al. Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest 2014; 124: 3945–3959.
47. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. Blood 2012; 119: 3084–3096.
48. van der Poel CE, Karssemeijer RA, Boross P, van der Linden JA, Blokland M, van de Winkel JG et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. Blood 2010; 116: 5327–5333.
49. van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH. Functional characteristics of the high affinity IgG receptor, FcγRI. J Immunol 2011; 186: 2699–2704.
50. Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 2002; 16: 379–389.
51. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002; 16: 391–402.
52. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 2006; 66: 1261–1264.
53. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006; 203: 743–753.
54. McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T et al. The importance of human FcγRI in mediating protection to malaria. PLoS Pathog 2007; 3: e72.
55. Baudino L, Nimmerjahn F, Azeredo da Silveira S, Martinez-Soria E, Saito T, Carroll M et al. Differential contribution of three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a-and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol 2008; 180: 1948–1953.
56. Mancardi DA, Albanesi M, Jonsson F, Iannascoli B, Van Rooijen N, Kang X et al. The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 2013; 121: 1563–1573.
57. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 2014; 14: 94–108.
58. Gul N, Babes L, Siegmund K, Korthouwer R, Bogels M, Braster R et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 2014; 124: 812–823.
59. Ting LM, Kim AC, Cattamanchi A, Ernst JD. Mycobacterium tuberculosis inhibits IFN-γ transcriptional responses without inhibiting activation of STAT1. J Immunol 1999; 163: 3898–3906.
60. Bruhns P, Jonsson F. Mouse and human FcR effector functions. Immunol Rev 2015; 268: 25–51.
61. Jouvin-Marche E, Morgado MG, Leguern C, Voegtle D, Bonhomme F, Cazenave PA. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics 1989; 29: 92–97.
62. Morgado MG, Cam P, Gris-Liebe C, Cazenave PA, Jouvin-Marche E. Further evidence that BALB/c and C57BL/6 γ2a genes originate from two distinct isotypes. EMBO J 1989; 8: 3245–3251.
63. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 2012; 13: 1118–1128.
64. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3578–3585.
65. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 2003; 40: 585–593.
66. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164: 4178–4184.
67. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001; 276: 6591–6604.
68. Baudino L, Nimmerjahn F, Shinohara Y, Furukawa J, Petry F, Verbeek JS et al. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J Immunol 2008; 181: 4107–4112.
69. Baudino L, Shinohara Y, Nimmerjahn F, Furukawa J, Nakata M, Martinez-Soria E et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol 2008; 181: 6664–6669.
70. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 496: 445–455.
71. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275–290.
72. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70: 3209–3217.
73. Kyono WT, de Jong R, Park RK, Liu Y, Heisterkamp N, Groffen J et al. Differential interaction of Crkl with Cbl or C3G, Hef-1, and γ subunit immunoreceptor tyrosine-based activation motif in signaling of myeloid high affinity Fc receptor for IgG (FcγRI). J Immunol 1998; 161: 5555–5563.
74. Park RK, Kyono WT, Liu Y, Durden DL. CBL-GRB2 interaction in myeloid immunoreceptor tyrosine activation motif signaling. J Immunol 1998; 160: 5018–5027.
75. Shen H, Clauss M, Ryan J, Schmidt AM, Tijburg P, Borden L et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 1993; 81: 2767–2773.
76. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336–3343.
77. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629–17634.
78. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349–9354.
79. Kobayashi S, Sawano A, Nojima Y, Shibuya M, Maru Y. The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1). FASEB J 2004; 18: 929–931.
80. Thien CB, Blystad FD, Zhan Y, Lew AM, Voigt V, Andoniou CE et al. Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion. EMBO J 2005; 24: 3807–3819.
81. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443–446.
82. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 2012; 12: 13.
83. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23: 277–286.
84. Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity 1996; 5: 181–188.
85. Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D et al. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci USA 2010; 107: 19396–19401.
86. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184: 512–520.
87. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332: 738–740.
88. Yasuma R, Cicatiello V, Mizutani T. Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal Transduct Target Ther 2016; 1: (in press).
89. Lu J, Ellsworth JL, Hamacher N, Oak SW, Sun PD. Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem 2011; 286: 40608–40613.
90. Grossniklaus HE, Cingle KA, Yoon YD, Ketkar N, L'Hernault N, Brown S. Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy. Arch Ophthalmol 2000; 118: 625–629.
91. Tan PS, Gavin AL, Barnes N, Sears DW, Vremec D, Shortman K et al. Unique monoclonal antibodies define expression of FcγRI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 2003; 170: 2549–2556.
92. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fcγ receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013; 6: 1.